The Efficacy of Dalbavancin and Impact on Hospitalization and Treatment Costs in Patients with ABSSSI

Overview

Journal Glob Reg Health Technol Assess

Specialty Health Services

Date 2024 Aug 5

PMID 39100524

Authors

Sergio Carbonara

Affiliations

Soon will be listed here.

Abstract

Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.

References

Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L . Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019; 47(6):1013-1020. DOI: 10.1007/s15010-019-01354-x. View

Poliseno M, Bavaro D, Brindicci G, Luzzi G, Carretta D, Spinarelli A . Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections. Clin Drug Investig. 2021; 41(5):437-448. PMC: 8059686. DOI: 10.1007/s40261-021-01028-3. View

Jagan N, Pendru R, Jyothinath K . Efficacy of Dalbavancin and Telavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections. Maedica (Bucur). 2018; 13(3):208-212. PMC: 6290182. DOI: 10.26574/maedica.2018.13.3.208. View

Durante-Mangoni E, Gambardella M, Iula V, De Stefano G, Corrado M, Esposito V . Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020; 56(4):106107. DOI: 10.1016/j.ijantimicag.2020.106107. View

Papavramidis T, Gentile I, Cattelan A, Magnasco L, Viale P, Francisci D . REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI. Int J Antimicrob Agents. 2023; 61(4):106746. DOI: 10.1016/j.ijantimicag.2023.106746. View

Bai F, Mazzitelli M, Silvola S, Raumer F, Restelli U, Croce D . Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals. JAC Antimicrob Resist. 2023; 5(2):dlad044. PMC: 10116602. DOI: 10.1093/jacamr/dlad044. View

Wilke M, Worf K, Preisendorfer B, Heinlein W, Kast T, Bodmann K . Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data. GMS Infect Dis. 2019; 7:Doc03. PMC: 6839362. DOI: 10.3205/id000043. View

Streifel A, Sikka M, Bowen C, Lewis 2nd J . Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019; 54(5):652-654. DOI: 10.1016/j.ijantimicag.2019.08.007. View

Arrieta-Loitegui M, Caro-Teller J, Ortiz-Perez S, Lopez-Medrano F, San Juan-Garrido R, Ferrari-Piquero J . Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm. 2020; 29(1):55-58. PMC: 8717798. DOI: 10.1136/ejhpharm-2020-002315. View

10.

Gonzalez P, Rappo U, Akinapelli K, McGregor J, Puttagunta S, Dunne M . Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs. Drugs Context. 2018; 7:212559. PMC: 6292452. DOI: 10.7573/dic.212559. View

11.

Talan D, Mower W, Lovecchio F, Rothman R, Steele M, Keyloun K . Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. Acad Emerg Med. 2021; 28(10):1108-1117. PMC: 8597095. DOI: 10.1111/acem.14258. View

12.

Koziatek C, Mohan S, Caspers C, Swaminathan A, Swartz J . Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit. Am J Emerg Med. 2017; 36(7):1312-1314. DOI: 10.1016/j.ajem.2017.11.037. View

13.

Boucher H, Wilcox M, Talbot G, Puttagunta S, Das A, Dunne M . Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014; 370(23):2169-79. DOI: 10.1056/NEJMoa1310480. View

14.

Simonetti O, Rizzetto G, Molinelli E, Cirioni O, Offidani A . Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization. Ther Clin Risk Manag. 2021; 17:223-232. PMC: 7997409. DOI: 10.2147/TCRM.S271445. View

15.

Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J . Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015; 18(12):1092-101. DOI: 10.3111/13696998.2015.1078339. View

16.

Dunne M, Talbot G, Boucher H, Wilcox M, Puttagunta S . Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Saf. 2015; 39(2):147-57. PMC: 4735234. DOI: 10.1007/s40264-015-0374-9. View

17.

Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A . Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019; 81:210-214. DOI: 10.1016/j.ijid.2019.02.013. View

18.

Bosso J, Casapao A, Edwards J, Klinker K, McCoy C, Nicolau D . Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. Hosp Pract (1995). 2016; 44(4):183-189. DOI: 10.1080/21548331.2016.1230466. View

19.

Oliva A, Carbonara S, Cianci V, Crapis M, Di Domenico E, Falcone M . Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin. Expert Rev Anti Infect Ther. 2023; 21(7):703-721. DOI: 10.1080/14787210.2023.2214727. View

20.

Marcellusi A, Bini C, Andreoni M, Sarmati L, Espin J, Horcajada J . Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. Clin Drug Investig. 2020; 40(4):305-318. DOI: 10.1007/s40261-020-00891-w. View